Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07774507 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07774507 · ClinicalTrials.gov record · last posted 2026-08-20

Twenty-four Hour Movement Behaviors and Atherosclerotic Risk

Study acronym: PASSARO
StatusRecruiting
PhaseNot specified
Started2026-09-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This observational study aims to investigate how 24-hour movement behaviors are associated with atherosclerotic risk in adults with rheumatoid arthritis. These behaviors include physical activity, sedentary behavior, and sleep. The main questions it aims to answer are: * Are 24-hour movement behaviors, both individually and in combination, associated with indicators of atherosclerotic risk in adults with RA? * Do changes in 24-hour movement behaviors over 12 months relate to changes in indicators of atherosclerotic risk? Participants will: * Wear activity monitors (accelerometers) continuously for 7 days to measure physical activity, sedentary behavior, and sleep. * Answer questionnaires about their health and lifestyle. * Undergo cardiovascular assessments, body composition measurements, physical fitness tests, and blood tests to measure lipid and inflammatory profile. * Return 12 months later for follow-up assessments. The researchers hope this study will improve understanding of how daily movement behaviors influence cardiovascular health in people with rheumatoid arthritis. The findings may help inform future recommendations to promote healthier movement behaviors and improve cardiovascular risk management in this population.

Protocol amendment history 1 change detected by DataLookout

2026-08-21
notable
Enrollment reopened
Trial Details
NCT Number NCT07774507
Lead Sponsor São Paulo State University
Conditions Cardiovascular Risk Assessment, Rheumatoid Arthritis (RA), 24-Hour Movement Guidelines
Enrollment 150 participants
Start Date 2026-09-01
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-20